What is Comirnaty LP.8.1 30 µg/dose inj. disp. i.m. vial used for?

( ARTG ) Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, in individuals 6 months of age and older.,The use of this vaccine should be in accordance with official recommendations.

What are the side effects of Comirnaty LP.8.1 30 µg/dose inj. disp. i.m. vial?

This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get. You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems . For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme

Who manufactures Comirnaty LP.8.1 30 µg/dose inj. disp. i.m. vial?

BioNTech Manufacturing GmbH (BE)

What ATC class does Comirnaty LP.8.1 30 µg/dose inj. disp. i.m. vial belong to?

Comirnaty LP.8.1 30 µg/dose inj. disp. i.m. vial: ATC J07BN01 Covid-19, RNA-based Vaccine. ATC is the WHO Anatomical Therapeutic Chemical classification — it groups drugs by organ system and pharmacological mechanism.

OTC

Comirnaty LP.8.1 30 µg/dose inj. disp. i.m. vial

Dispersion for injection

INN: 5'-capped mRNA encoding SARS-CoV-2, Variant LP.8.1., Spike Protein, pre-fusion stabilised (K981P and V982P)

Data updated: 2026-04-11

Available in:

🇩🇪🇬🇧🇫🇷

Form

Dispersion for injection

Dosage

—

Route

Intramuscular use

Storage

—

About This Product

User Reviews

Reviews reflect personal experiences and are not medical advice. Always consult your doctor.